The FDA on December 18, 2020 approved the first oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, ORGOVYX® for adult patients with advanced prostate cancer. ORGOVYX® is a product of Myovant Sciences, Inc.
Bottom Ad
Advertisement
Subscribe
